Facilitating strategic connections
that drive life science dealmaking.
8 Global events
11,644 Executive-level attendees attracted
48,347 One-to-one partnering meetings held
6,673 Attending companies
60 Countries represented
12,193 Licensing opportunities on offer
Over the past 3 years, biopharma companies have inked more than 500 alliances where potential deal value of more than $50 million was disclosed. In this second edition, Chris Morrison expands on his analysis of game-changing deals with the addition of the most recent mega-deals as well as the aggregate effects of all alliances and acquisitions.
What does it take to launch a successful biotech company? This sourcebook gathers advice from some of the industry’s best sources to help entrepreneurs solve some of the toughest—and often unexpected—challenges of creating a life sciences startup.
Let's face it, Celegene was an important market maker for partnering deals. That is why many a biotech (and their investors) lament the day Celegene was acquired by BMS. So what happens now? Will the deal flow void be filled by other companies? If so, which ones?
We consistently provide valuable in-depth insight and analysis on the most recent trends in life science and partnering. Don't miss the latest releases!
partneringONE is even more powerful than before. New features and functionality will increase your productivity and improve your partnering experience. Look out for a mobile-responsive platform, time-saving message templates and enhanced search capabilities and collaboration tools.
FIND OUT MORE
Our network of more than 40,000 high-value dealmakers, companies and assets from around the world are looking for "best-fit" partners.
Find out more© 2008- 2019 EBD GmbH/EBD Group
EBD Group is part of
is an Informa business